ABSTRACT
We report a case of encephalopathy that was suspected to be caused by chemotherapy for liver metastasis from sigmoid colon cancer. A 72-year-old male was suspected that he had drug-induced eukoencephalopathy because he was presented with physical disorders during the FOLFOX/bevacizumab therapy. Although a brain MRI revealed Alzheimer disease, leukoencephalopathy was not excluded from the diagnoses due to a fact that his findings could not be compared before and after the chemotherapy. If leukoencephalopathy was suspected, chemotherapy should have been discontinued as soon as possible. Although a partial response was achieved, chemotherapy had to be discontinued in this case. The cases whose physical and neurological disorders were at risk due to a past history need an examination for nervous system in order to make a comparison with the findings before and after chemotherapy.
Subject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Dementia/chemically induced , Sigmoid Neoplasms/drug therapy , Aged , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Leucovorin/adverse effects , Leucovorin/therapeutic use , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Male , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/therapeutic use , Sigmoid Neoplasms/pathology , Sigmoid Neoplasms/surgeryABSTRACT
Summer-type hypersensitivity pneumonitis (SHP) is the most prevalent type of hypersensitivity pneumonitis in Japan. Its main causative antigenic organisms are Trichosporon species. Although this disease had been thought to be unique to Japan, more than ten patients were found in Korea, recently. It is expected that patients with SHP will be found elsewhere in the Temperate Zones, the tropics or in the subtropics. It is important in diagnosing SHP to prove specific antibody against causative antigen in patient's serum, for the existence of specific antibody indicates the patient had been exposed to, and sensitized to the antigen. In the present study, we devised Enzyme-linked Immunosorbent Assay system using monoclonal antibody specific to T. asahii, to measure antibodies against T. asahii. We evaluated the usefulness of the system by using sera from patients with SHP, patients with other pulmonary diseases, or healthy volunteers. We found specificity and sensitivity of the system were 92.8% and 92.3%, respectively. This system was proved to be useful in diagnosing SHP.
